Use of an adeno-associated virus serotype Anc80 to provide durable cure of phenylketonuria in a mouse model

Phenylketonuria (PKU) is the most common inborn error of metabolism of the liver, and results from mutations of both alleles of the phenylalanine hydroxylase gene (PAH). As such, it is a suitable target for gene therapy via gene delivery with a recombinant adeno-associated virus (AAV) vector. Here w...

Descripción completa

Detalles Bibliográficos
Autores: Kaiser, R.A. (Robert A.)|||/items/6afaab0e-3d47-4541-a40f-947f73ea3b45, Weber, N.D. (Nicholas D.)|||/items/e84412f9-7e7c-4020-b16d-668a3fb5ee6a, Trigueros-Motos, L. (Laia)|||/items/89a0169c-ea93-47f8-8ddc-3cc131ddf8ff, Allen, K.L. (Kari L.)|||/items/c26aec3c-708d-4b93-8b93-bbd4bb96efb6, Martinez, M. (Michael)|||/items/dd67ec2e-30a3-4713-9ded-add0d05bc93f, Cao, W. (William)|||/items/7fbfad2f-27f3-41ce-8305-ac2ec305b263, VanLith, C.J. ( Caitlin J.)|||/items/3dac9023-ec85-431e-8501-97e2a68abb5f, Hillin, L.G. (Lori G.)|||/items/aa6fe4bd-dfd9-46fe-90cf-e4636dabe3ae, Douar, A. (Anne)|||/items/a33dbbfb-3e78-4cfa-8f99-0652529ecd64, González-Aseguinolaza, G. (Gloria)|||/items/cb28732d-02bf-4339-ab60-ff738ee191ac, Aldabe, R. (Rafael)|||/items/ef60614f-7fda-4565-bd52-0ace35b55292, Lillegard, J.B. (Joseph B.)|||/items/d2ed228b-2b19-4910-a1bf-7f690782040a
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Universidad de Navarra
Repositorio:Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:inglés
OAI Identifier:oai:dadun.unav.edu:10171/114668
Acceso en línea:https://hdl.handle.net/10171/114668
Access Level:acceso abierto
Palabra clave:Anc80
Adeno-associated virus (AAV) vector
Gene therapy
Inborn error of metabolism
Phenylketonuria
id ES_22e8bd658da2d02008079b083e9953e9
oai_identifier_str oai:dadun.unav.edu:10171/114668
network_acronym_str ES
network_name_str España
repository_id_str
spelling Use of an adeno-associated virus serotype Anc80 to provide durable cure of phenylketonuria in a mouse modelKaiser, R.A. (Robert A.)|||/items/6afaab0e-3d47-4541-a40f-947f73ea3b45Weber, N.D. (Nicholas D.)|||/items/e84412f9-7e7c-4020-b16d-668a3fb5ee6aTrigueros-Motos, L. (Laia)|||/items/89a0169c-ea93-47f8-8ddc-3cc131ddf8ffAllen, K.L. (Kari L.)|||/items/c26aec3c-708d-4b93-8b93-bbd4bb96efb6Martinez, M. (Michael)|||/items/dd67ec2e-30a3-4713-9ded-add0d05bc93fCao, W. (William)|||/items/7fbfad2f-27f3-41ce-8305-ac2ec305b263VanLith, C.J. ( Caitlin J.)|||/items/3dac9023-ec85-431e-8501-97e2a68abb5fHillin, L.G. (Lori G.)|||/items/aa6fe4bd-dfd9-46fe-90cf-e4636dabe3aeDouar, A. (Anne)|||/items/a33dbbfb-3e78-4cfa-8f99-0652529ecd64González-Aseguinolaza, G. (Gloria)|||/items/cb28732d-02bf-4339-ab60-ff738ee191acAldabe, R. (Rafael)|||/items/ef60614f-7fda-4565-bd52-0ace35b55292Lillegard, J.B. (Joseph B.)|||/items/d2ed228b-2b19-4910-a1bf-7f690782040aAnc80Adeno-associated virus (AAV) vectorGene therapyInborn error of metabolismPhenylketonuriaPhenylketonuria (PKU) is the most common inborn error of metabolism of the liver, and results from mutations of both alleles of the phenylalanine hydroxylase gene (PAH). As such, it is a suitable target for gene therapy via gene delivery with a recombinant adeno-associated virus (AAV) vector. Here we use the synthetic AAV vector Anc80 via systemic administration to deliver a functional copy of a codon-optimized human PAH gene, with or without an intron spacer, to the Pahenu2 mouse model of PKU. Dose-dependent transduction of the liver and expression of PAH mRNA were present with both vectors, resulting in significant and durable reduction of circulating phenylalanine, reaching near control levels in males. Coat color of treated Pahenu2 mice reflected an increase in pigmentation from brown to the black color of control animals, further indicating functional restoration of phenylalanine metabolism and its byproduct melanin. There were no adverse effects associated with administration of AAV up to 5 × 1012 VG/kg, the highest dose tested. Only minor and/or transient variations in some liver enzymes were observed in some of the AAV-dosed animals which were not associated with pathology findings in the liver. Finally, there was no impact on cell turnover or apoptosis as evaluated by Ki-67 and TUNEL staining, further supporting the safety of this approach. This study demonstrates the therapeutic potential of AAV Anc80 to safely and durably cure PKU in a mouse model, supporting development for clinical consideration.Wiley Periodicals LLC.Dadun. Depósito Académico Digital Universidad de Navarra20212021-01-0120212021-01-01journal articlehttp://purl.org/coar/resource_type/c_6501info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10171/114668reponame:Dadun. Depósito Académico Digital de la Universidad de Navarrainstname:Universidad de NavarraInglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:dadun.unav.edu:10171/1146682026-06-21T12:47:57Z
dc.title.none.fl_str_mv Use of an adeno-associated virus serotype Anc80 to provide durable cure of phenylketonuria in a mouse model
title Use of an adeno-associated virus serotype Anc80 to provide durable cure of phenylketonuria in a mouse model
spellingShingle Use of an adeno-associated virus serotype Anc80 to provide durable cure of phenylketonuria in a mouse model
Kaiser, R.A. (Robert A.)|||/items/6afaab0e-3d47-4541-a40f-947f73ea3b45
Anc80
Adeno-associated virus (AAV) vector
Gene therapy
Inborn error of metabolism
Phenylketonuria
title_short Use of an adeno-associated virus serotype Anc80 to provide durable cure of phenylketonuria in a mouse model
title_full Use of an adeno-associated virus serotype Anc80 to provide durable cure of phenylketonuria in a mouse model
title_fullStr Use of an adeno-associated virus serotype Anc80 to provide durable cure of phenylketonuria in a mouse model
title_full_unstemmed Use of an adeno-associated virus serotype Anc80 to provide durable cure of phenylketonuria in a mouse model
title_sort Use of an adeno-associated virus serotype Anc80 to provide durable cure of phenylketonuria in a mouse model
dc.creator.none.fl_str_mv Kaiser, R.A. (Robert A.)|||/items/6afaab0e-3d47-4541-a40f-947f73ea3b45
Weber, N.D. (Nicholas D.)|||/items/e84412f9-7e7c-4020-b16d-668a3fb5ee6a
Trigueros-Motos, L. (Laia)|||/items/89a0169c-ea93-47f8-8ddc-3cc131ddf8ff
Allen, K.L. (Kari L.)|||/items/c26aec3c-708d-4b93-8b93-bbd4bb96efb6
Martinez, M. (Michael)|||/items/dd67ec2e-30a3-4713-9ded-add0d05bc93f
Cao, W. (William)|||/items/7fbfad2f-27f3-41ce-8305-ac2ec305b263
VanLith, C.J. ( Caitlin J.)|||/items/3dac9023-ec85-431e-8501-97e2a68abb5f
Hillin, L.G. (Lori G.)|||/items/aa6fe4bd-dfd9-46fe-90cf-e4636dabe3ae
Douar, A. (Anne)|||/items/a33dbbfb-3e78-4cfa-8f99-0652529ecd64
González-Aseguinolaza, G. (Gloria)|||/items/cb28732d-02bf-4339-ab60-ff738ee191ac
Aldabe, R. (Rafael)|||/items/ef60614f-7fda-4565-bd52-0ace35b55292
Lillegard, J.B. (Joseph B.)|||/items/d2ed228b-2b19-4910-a1bf-7f690782040a
author Kaiser, R.A. (Robert A.)|||/items/6afaab0e-3d47-4541-a40f-947f73ea3b45
author_facet Kaiser, R.A. (Robert A.)|||/items/6afaab0e-3d47-4541-a40f-947f73ea3b45
Weber, N.D. (Nicholas D.)|||/items/e84412f9-7e7c-4020-b16d-668a3fb5ee6a
Trigueros-Motos, L. (Laia)|||/items/89a0169c-ea93-47f8-8ddc-3cc131ddf8ff
Allen, K.L. (Kari L.)|||/items/c26aec3c-708d-4b93-8b93-bbd4bb96efb6
Martinez, M. (Michael)|||/items/dd67ec2e-30a3-4713-9ded-add0d05bc93f
Cao, W. (William)|||/items/7fbfad2f-27f3-41ce-8305-ac2ec305b263
VanLith, C.J. ( Caitlin J.)|||/items/3dac9023-ec85-431e-8501-97e2a68abb5f
Hillin, L.G. (Lori G.)|||/items/aa6fe4bd-dfd9-46fe-90cf-e4636dabe3ae
Douar, A. (Anne)|||/items/a33dbbfb-3e78-4cfa-8f99-0652529ecd64
González-Aseguinolaza, G. (Gloria)|||/items/cb28732d-02bf-4339-ab60-ff738ee191ac
Aldabe, R. (Rafael)|||/items/ef60614f-7fda-4565-bd52-0ace35b55292
Lillegard, J.B. (Joseph B.)|||/items/d2ed228b-2b19-4910-a1bf-7f690782040a
author_role author
author2 Weber, N.D. (Nicholas D.)|||/items/e84412f9-7e7c-4020-b16d-668a3fb5ee6a
Trigueros-Motos, L. (Laia)|||/items/89a0169c-ea93-47f8-8ddc-3cc131ddf8ff
Allen, K.L. (Kari L.)|||/items/c26aec3c-708d-4b93-8b93-bbd4bb96efb6
Martinez, M. (Michael)|||/items/dd67ec2e-30a3-4713-9ded-add0d05bc93f
Cao, W. (William)|||/items/7fbfad2f-27f3-41ce-8305-ac2ec305b263
VanLith, C.J. ( Caitlin J.)|||/items/3dac9023-ec85-431e-8501-97e2a68abb5f
Hillin, L.G. (Lori G.)|||/items/aa6fe4bd-dfd9-46fe-90cf-e4636dabe3ae
Douar, A. (Anne)|||/items/a33dbbfb-3e78-4cfa-8f99-0652529ecd64
González-Aseguinolaza, G. (Gloria)|||/items/cb28732d-02bf-4339-ab60-ff738ee191ac
Aldabe, R. (Rafael)|||/items/ef60614f-7fda-4565-bd52-0ace35b55292
Lillegard, J.B. (Joseph B.)|||/items/d2ed228b-2b19-4910-a1bf-7f690782040a
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Dadun. Depósito Académico Digital Universidad de Navarra
dc.subject.none.fl_str_mv Anc80
Adeno-associated virus (AAV) vector
Gene therapy
Inborn error of metabolism
Phenylketonuria
topic Anc80
Adeno-associated virus (AAV) vector
Gene therapy
Inborn error of metabolism
Phenylketonuria
description Phenylketonuria (PKU) is the most common inborn error of metabolism of the liver, and results from mutations of both alleles of the phenylalanine hydroxylase gene (PAH). As such, it is a suitable target for gene therapy via gene delivery with a recombinant adeno-associated virus (AAV) vector. Here we use the synthetic AAV vector Anc80 via systemic administration to deliver a functional copy of a codon-optimized human PAH gene, with or without an intron spacer, to the Pahenu2 mouse model of PKU. Dose-dependent transduction of the liver and expression of PAH mRNA were present with both vectors, resulting in significant and durable reduction of circulating phenylalanine, reaching near control levels in males. Coat color of treated Pahenu2 mice reflected an increase in pigmentation from brown to the black color of control animals, further indicating functional restoration of phenylalanine metabolism and its byproduct melanin. There were no adverse effects associated with administration of AAV up to 5 × 1012 VG/kg, the highest dose tested. Only minor and/or transient variations in some liver enzymes were observed in some of the AAV-dosed animals which were not associated with pathology findings in the liver. Finally, there was no impact on cell turnover or apoptosis as evaluated by Ki-67 and TUNEL staining, further supporting the safety of this approach. This study demonstrates the therapeutic potential of AAV Anc80 to safely and durably cure PKU in a mouse model, supporting development for clinical consideration.
publishDate 2021
dc.date.none.fl_str_mv 2021
2021-01-01
2021
2021-01-01
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/10171/114668
url https://hdl.handle.net/10171/114668
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Wiley Periodicals LLC.
publisher.none.fl_str_mv Wiley Periodicals LLC.
dc.source.none.fl_str_mv reponame:Dadun. Depósito Académico Digital de la Universidad de Navarra
instname:Universidad de Navarra
instname_str Universidad de Navarra
reponame_str Dadun. Depósito Académico Digital de la Universidad de Navarra
collection Dadun. Depósito Académico Digital de la Universidad de Navarra
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869404608949911552
score 15,812455